Drug Profile
SDZ MTH 958
Alternative Names: MTH 958Latest Information Update: 01 Sep 1998
Price :
$50
*
At a glance
- Originator Novartis
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Thrombosis; Transplant rejection
Most Recent Events
- 01 Sep 1998 No-Development-Reported for Coronary artery restenosis in Switzerland (Unknown route)
- 01 Sep 1998 No-Development-Reported for Thrombosis in Switzerland (Unknown route)
- 10 Aug 1998 No-Development-Reported for Transplant rejection in Switzerland (Unknown route)